World Medicine Ranks 3rd with 125 Brands in Türkiye R&D 500 Research

Türkiye’s pharmaceutical export champion World Medicine ranked 3rd in the overall ranking with 125 registered brands in the Türkiye R&D 500 Research, and came 2nd among companies producing the most projects with 611 R&D projects. The company’s R&D investments, intellectual property strength and innovation-focused growth strategy drew attention.

The Türkiye R&D 500 Research, which has been presenting the R&D performance, investments and progress of Turkish business in the innovation ecosystem with comprehensive data for 13 years, has concluded. In the research, which evaluates criteria such as R&D expenditures, R&D employment, number of projects and intellectual property performance, World Medicine, one of the leading companies in the pharmaceutical sector, achieved a significant success.

World Medicine ranked 3rd in the overall ranking with 125 registered brands, while the 611 projects the company carried out placed it 2nd among companies producing the most projects. The results revealed the scale of the company’s work in R&D, innovation, value-added production and intellectual property.

World Medicine Vice Chairman of the Board of Directors Sohrab Mammadli stated that the research results are an important indicator of the company’s R&D and innovation-focused growth strategy.

Mammadli said that they act with the vision of positioning Türkiye not only as a production center but also as a regional and global R&D, innovation and logistics hub, and stated the following:

“As World Medicine, we act with the vision of making Türkiye not only a production center but a regional and global R&D, innovation and logistics hub. Ranking 3rd with our 125 brands in the Türkiye R&D 500 Research is a concrete indicator of the strategic importance we attach to intellectual property and our innovative product development processes.”

Noting that the company allocates approximately 5 percent of its turnover to R&D activities, Mammadli said that investments in biotechnology and oncology also hold an important place in the company’s future growth strategy.

“By combining our scientific strength with our organizational capability and expanding product portfolio, we are moving forward with confident steps toward becoming a global reference brand in the world health arena.”

World Medicine supports its R&D and innovation efforts with a strong production infrastructure and export capacity. While developing its production activities in Türkiye, the company is also strengthening its position among industrial organizations with its national and international performance.

Sohrab Mammadli noted that the company’s results in various independent research studies support this growth performance, and made the following assessment:

“We combine our R&D and innovation investments with our strong production infrastructure. Our performance in national and international independent research studies also reinforces our position among Türkiye’s leading industrial organizations.”

World Medicine ranked 318th in the Istanbul Chamber of Industry’s (İSO) Türkiye’s Top 500 Industrial Enterprises research. The company also ranked 477th in the Capital 500 research conducted by Capital.

Mammadli stated that these results reveal both the company’s contribution to the Turkish economy and its sustainable financial growth capacity.

World Medicine, which has been operating in Türkiye since 2011, continues its work in line with innovative product development and a sustainable quality approach.

The company, which has a portfolio of more than 600 pharmacological products in different therapeutic areas, primarily ophthalmology, neurology, endocrinology, cardiology, rheumatology, gastroenterology, urology and chest diseases, exports its products to more than 65 countries.

With its R&D and production investments, World Medicine is turning Türkiye into the company’s main production and headquarters base, while aiming to expand its activities in the global health sector and its export markets.